Summary
Eli Lilly and Company's 2013 10-K filing reveals a company navigating patent expirations while investing heavily in research and development for future growth. The company reported a 2% increase in worldwide revenue to $23.11 billion, driven by strong performance in key products like Cialis, Humalog, and Trajenta, alongside its animal health division. Net income saw a significant 15% increase to $4.68 billion, largely due to improved gross margins and lower operating expenses, further boosted by a lower effective tax rate and share repurchases. However, the report also highlights significant challenges. Cymbalta lost U.S. patent exclusivity in December 2013, leading to immediate generic competition and expected rapid revenue declines. Evista is also set to face similar pressures with patent expiration in March 2014. The company is actively managing these patent cliffs through robust R&D pipelines, with several promising candidates in late-stage development across therapeutic areas like diabetes, oncology, and neuroscience. Despite these challenges, Lilly's financial health appears solid, supported by strong cash flow and a commitment to returning value to shareholders through dividends and share repurchases.
Financial Highlights
53 data points| Revenue | $23.11B |
| Cost of Revenue | $4.91B |
| Gross Profit | $18.20B |
| R&D Expenses | $5.53B |
| SG&A Expenses | $7.13B |
| Interest Expense | $160.10M |
| Net Income | $4.68B |
| EPS (Basic) | $4.33 |
| EPS (Diluted) | $4.32 |
| Shares Outstanding (Basic) | 1.08B |
| Shares Outstanding (Diluted) | 1.08B |
Key Highlights
- 1Worldwide revenue grew 2% to $23.11 billion in 2013, with net income up 15% to $4.68 billion.
- 2Key product growth drivers included Cialis, Humalog, Trajenta, Alimta, and Forteo, along with the Elanco animal health division.
- 3Significant revenue erosion is expected for Cymbalta and Evista due to recent and upcoming patent expirations.
- 4Research and development expenses increased 5% to $5.53 billion, reflecting continued investment in new drug development.
- 5The company actively repurchased shares, repurchasing $1.70 billion in 2013.
- 6Lilly is managing its legal and regulatory environment, including ongoing patent litigation for Alimta and investigations into marketing practices.
- 7The company has a strong late-stage pipeline with multiple promising new molecular entities across various therapeutic areas.